Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.46 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.45 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | SDCBP | O00560 | 1/20 | 0.40 |
| ▸ | SDC2 | P34741 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.39 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1362409 | 0.82 | LMNA (0.41) | LMNAMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL186800 | 0.80 | MEN1 (0.53) | LMNAMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL1364983 | 0.77 | TSHR (0.46) | LMNAACMSDMEN1KMT2AHTT | |
| SCHEMBL3404714 | 0.77 | PRKCI (0.45) | PTGER4ACMSDADAMTS4DHODHSHMT1 | |
| SCHEMBL2957633 | 0.76 | HSD17B1 (0.51) | LMNAMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL4092283 | 0.76 | PTGER4 (0.52) | PTGER4ACMSDADAMTS4DHODHPRKCI | |
| SCHEMBL2952041 | 0.75 | HSD17B1 (0.52) | LMNAMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL2177213 | 0.73 | MEN1 (0.47) | LMNAMEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL12053395 | 0.73 | HDAC1 (0.45) | PTGER4ACMSD | |
| SCHEMBL1362512 | 0.73 | LMNA (0.46) | LMNAMEN1KMT2AHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071588-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8067408-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-11-29 | — | — | US | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE4B, PDE1A | LMNA 4824/4885PTGER4 26/4885ACMSD 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.